CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 60 enrolled
Drug / intervention
LY2541546 - IV +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01742078
NCT01742078Phase 1Completed
CompareCT.gov

A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2541546 in Healthy Postmenopausal Women

Eli Lilly and Company·interventional·Posted Dec 5, 2012·Updated Jan 23, 2019

In Brief

A Phase 1 clinical trial evaluating LY2541546 - IV, LY2541546 - SC, and 1 other intervention for Healthy. Completed, enrolled 60 participants across 2 sites.

Detailed Summary

The purpose of this study is to determine if a single dose of LY2541546 has any side effects on the body and to determine how long and how much LY2541546 stays in the bloodstream of the body.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 5, 2012
Enrollment StartJun 1, 2008
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 13.6 years ago

Interventions

LY2541546 - IVdrug

Administered IV

LY2541546 - SCdrug

Administered SC

Placebodrug

Administered IV or SC